Finance

Beta
Lists
Q4 2026 earnings • released • EPS beat +14.54% • Revenue beat +3.05%
See results
GLENMARK:NSE
Glenmark Pharmaceuticals Ltd
₹2,189.00
+0.39%
(+8.40) 1D
Jun 5, 9:32:41 AM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLENMARK...
Open
₹2,191.90
High
₹2,216.20
Low
₹2,183.40
Mkt. cap
617.74B
Avg. vol.
799.45K
Volume
66.73K
Dividend
0.17%
Quarterly dividend
₹0.94
Ex-dividend date
Oct 3, 2025
P/E ratio
45.38
52-wk high
₹2,474.00
52-wk low
₹1,512.80
EPS
₹48.24
Shares outstanding
0.00
No. of employees
16K
Open
₹2,191.90
High
₹2,216.20
Low
₹2,183.40
Mkt. cap
617.74B
Avg. vol.
799.45K
Volume
66.73K
Dividend
0.17%
Quarterly dividend
₹0.94
Ex-dividend date
Oct 3, 2025
P/E ratio
45.38
52-wk high
₹2,474.00
52-wk low
₹1,512.80
EPS
₹48.24
Shares outstanding
0.00
No. of employees
16K
News stories
From sources across the web
Profile
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Wikipedia
About Glenmark Pharmaceuticals Ltd
CEO-
Employees15.8K
FoundedNov 18, 1977
Headquarters-
SectorPharmaceutical industry
Websiteglenmarkpharma.com
Last report
May 31, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
₹20.96 / ₹18.30
+14.54%beat
Revenue / Est. (INR)
39.60B / 38.42B
+3.05%beat
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
32.64B
60.47B
39.01B
39.60B
Cost of goods sold
10.16B
12.65B
12.95B
11.72B
Cost of revenue
10.16B
12.65B
12.95B
11.72B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.63B
10.86B
8.41B
8.87B
Operating expense
17.98B
25.64B
18.90B
19.84B
Total operating expenses
28.14B
38.29B
31.85B
31.56B
Operating income
4.51B
22.18B
7.15B
8.04B
Other non operating income
264.42M
2.01B
444.65M
-
EBT including unusual items
955.78M
9.67B
5.34B
3.88B
EBT excluding unusual items
4.19B
23.53B
7.18B
7.61B
Income tax expense
486.05M
3.57B
1.31B
864.49M
Effective tax rate
50.85%
36.90%
24.49%
22.29%
Other operating expenses
9.06B
13.37B
8.94B
9.48B
Net income
468.71M
6.10B
4.03B
3.01B
Net profit margin
1.44%
10.09%
10.34%
7.61%
Earnings per share
7.29
-
19.21
20.96
Interest and investment income
-
-
-
-
Interest expense
-582.26M
-664.63M
-414.32M
-426.04M
Net interest expenses
-582.26M
-664.63M
-414.32M
-426.04M
Depreciation and amortization charges
1.30B
1.41B
1.54B
1.48B
EBITDA
5.72B
23.54B
7.80B
9.47B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer